AKTX
Akari Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$9.66
+18.09%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-166.5%
Return on equity
-80.2%
Return on assets
-160.7%
Return on invested capital
0.00x
Asset turnover
-$10.7M
Cash from operations
$3.37
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026